A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) who are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
The goal of this clinical research study is to learn if daratumumab can help to reduce the need for blood transfusions for up to 8 weeks in patients with myelodysplastic syndrome (MDS). The safety of daratummab will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 06/02/2017
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: